{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T02:33:32Z","timestamp":1790303612735,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2017,11,13]],"date-time":"2017-11-13T00:00:00Z","timestamp":1510531200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Center of Molecular immunology"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1007\/s12325-017-0631-7","type":"journal-article","created":{"date-parts":[[2017,11,13]],"date-time":"2017-11-13T02:29:47Z","timestamp":1510540187000},"page":"2638-2647","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Overall Survival of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma Treated with Nimotuzumab in the Real World"],"prefix":"10.1007","volume":"34","author":[{"given":"Yaimarelis","family":"Saumell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7747-1052","authenticated-orcid":false,"given":"Lizet","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram\u00f3n","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edadny","family":"Medina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaima","family":"Gal\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agustin","family":"Lage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,11,13]]},"reference":[{"issue":"1","key":"631_CR1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3322\/caac.21254","volume":"65","author":"RL Siegel","year":"2015","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5\u201329.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"631_CR2","doi-asserted-by":"crossref","first-page":"110","DOI":"10.21037\/acs.2017.03.18","volume":"6","author":"K Mehta","year":"2017","unstructured":"Mehta K, Bianco V, Awais O, Luketich JD, Pennathur A. Minimally invasive staging of esophageal cancer. Ann Cardiothorac Surg. 2017;6(2):110\u20138.","journal-title":"Ann Cardiothorac Surg"},{"issue":"16","key":"631_CR3","first-page":"236","volume":"3","author":"AG Murphy","year":"2015","unstructured":"Murphy AG, Lynch D, Kelly RJ. State of the art management of metastatic gastroesophageal cancer. Ann Transl Med. 2015;3(16):236.","journal-title":"Ann Transl Med"},{"issue":"3","key":"631_CR4","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S1470-2045(14)70028-2","volume":"15","author":"T Conroy","year":"2014","unstructured":"Conroy T, Galais MP, Raoul JL, Bouche O, Gourgou-Bourgade S, Douillard JY, et al. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5\/ACCORD17): final results of a randomised, phase 2\/3 trial. Lancet Oncol. 2014;15(3):305\u201314.","journal-title":"Lancet Oncol"},{"issue":"5","key":"631_CR5","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1093\/annonc\/mdr433","volume":"23","author":"A Herskovic","year":"2012","unstructured":"Herskovic A, Russell W, Liptay M, Fidler MJ, Al-Sarraf M. Esophageal carcinoma advances in treatment results for locally advanced disease: review. Ann Oncol. 2012;23(5):1095\u2013103.","journal-title":"Ann Oncol"},{"issue":"4","key":"631_CR6","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.athoracsur.2016.12.011","volume":"103","author":"R Dhupar","year":"2017","unstructured":"Dhupar R, Van Der Kraak L, Pennathur A, Schuchert MJ, Nason KS, Luketich JD, et al. Targeting immune checkpoints in esophageal cancer: a high mutational load tumor. Ann Thorac Surg. 2017;103(4):1340\u20139.","journal-title":"Ann Thorac Surg"},{"key":"631_CR7","doi-asserted-by":"crossref","first-page":"412","DOI":"10.12659\/MSM.902645","volume":"23","author":"X Han","year":"2017","unstructured":"Han X, Lu N, Pan Y, Xu J. Nimotuzumab combined with chemotherapy is a promising treatment for locally advanced and metastatic esophageal cancer. Med Sci Monit. 2017;23:412\u20138.","journal-title":"Med Sci Monit"},{"issue":"8","key":"631_CR8","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1111\/j.1524-4733.2009.00600.x","volume":"12","author":"ML Berger","year":"2009","unstructured":"Berger ML, Mamdani M, Atkins D, Johnson ML. Good research practices for comparative effectiveness research: defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources: the ISPOR good research practices for retrospective database analysis task force report\u2014part I. Value Health. 2009;12(8):1044\u201352.","journal-title":"Value Health"},{"issue":"7","key":"631_CR9","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S1470-2045(13)70136-0","volume":"14","author":"T Crosby","year":"2013","unstructured":"Crosby T, Hurt CN, Falk S, Gollins S, Mukherjee S, Staffurth J, et al. Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2\/3 randomised trial. Lancet Oncol. 2013;14(7):627\u201337.","journal-title":"Lancet Oncol"},{"issue":"10","key":"631_CR10","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1093\/annonc\/mdp069","volume":"20","author":"S Lorenzen","year":"2009","unstructured":"Lorenzen S, Schuster T, Porschen R, Al-Batran SE, Hofheinz R, Thuss-Patience P, et al. Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol. 2009;20(10):1667\u201373.","journal-title":"Ann Oncol"},{"issue":"8","key":"631_CR11","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S1470-2045(14)70271-2","volume":"15","author":"HE Ford","year":"2014","unstructured":"Ford HE. Gefitinib for oesophageal cancer: a cog in need of a wheel? Lancet Oncol. 2014;15(8):790\u20131.","journal-title":"Lancet Oncol"},{"issue":"4","key":"631_CR12","doi-asserted-by":"crossref","first-page":"373","DOI":"10.4161\/cbt.11.4.14097","volume":"11","author":"G Garrido","year":"2011","unstructured":"Garrido G, Tikhomirov IA, Rabasa A, Yang E, Gracia E, Iznaga N, et al. Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile. Cancer Biol Ther. 2011;11(4):373\u201382.","journal-title":"Cancer Biol Ther"},{"issue":"3\u20134","key":"631_CR13","first-page":"65","volume":"16","author":"A Lage","year":"2014","unstructured":"Lage A. Immunotherapy and complexity: overcoming barriers to control of advanced cancer. MEDICC Rev. 2014;16(3\u20134):65\u201372.","journal-title":"MEDICC Rev"},{"issue":"8","key":"631_CR14","doi-asserted-by":"crossref","first-page":"600","DOI":"10.4161\/cbt.19849","volume":"13","author":"M Ramos-Suzarte","year":"2012","unstructured":"Ramos-Suzarte M, Lorenzo-Luaces P, Lazo NG, Perez ML, Soriano JL, Gonzalez CE, et al. Treatment of malignant, non-resectable, epithelial origin esophageal tumours with the humanized anti- epidermal growth factor antibody nimotuzumab combined with radiation therapy and chemotherapy. Cancer Biol Ther. 2012;13(8):600\u20135.","journal-title":"Cancer Biol Ther"},{"issue":"34","key":"631_CR15","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1200\/JCO.2012.41.6701","volume":"30","author":"DL Hershman","year":"2012","unstructured":"Hershman DL, Wright JD. Comparative effectiveness research in oncology methodology: observational data. J Clin Oncol. 2012;30(34):4215\u201322.","journal-title":"J Clin Oncol"},{"issue":"3","key":"631_CR16","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","volume":"46","author":"PC Austin","year":"2011","unstructured":"Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res. 2011;46(3):399\u2013424.","journal-title":"Multivar Behav Res"},{"issue":"3","key":"631_CR17","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1081\/SAC-200068372","volume":"34","author":"JM Mar\u00edn","year":"2005","unstructured":"Mar\u00edn JM, Rodr\u00edguez-Bernal MT, Wiper P. Using weibull mixture distributions to model heterogeneous survival data. Commun Stat Simul Comput. 2005;34(3):673\u201384.","journal-title":"Commun Stat Simul Comput."},{"issue":"2","key":"631_CR18","doi-asserted-by":"crossref","first-page":"82","DOI":"10.4103\/2229-516X.157148","volume":"5","author":"R Mahajan","year":"2015","unstructured":"Mahajan R. Real world data: additional source for making clinical decisions. Int J Appl Basic Med Res. 2015;5(2):82.","journal-title":"Int J Appl Basic Med Res"},{"issue":"16","key":"631_CR19","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1002\/sim.5705","volume":"32","author":"PC Austin","year":"2013","unstructured":"Austin PC. The performance of different propensity score methods for estimating marginal hazard ratios. Stat Med. 2013;32(16):2837\u201349.","journal-title":"Stat Med"},{"key":"631_CR20","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.1598","author":"M Suntharalingam","year":"2014","unstructured":"Suntharalingam M, Winter K, Ilson D, Dicker AP, Kachnic L, Konski A et al. Effect of the addition of cetuximab to paclitaxel, cisplatin, and radiation therapy for patients with esophageal cancer: the NRG oncology RTOG 0436 phase 3 randomized clinical trial. JAMA Oncol. 2014. \n                        https:\/\/doi.org\/10.1001\/jamaoncol.2017.1598\n                        \n                    .","journal-title":"JAMA Oncol."},{"key":"631_CR21","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.2147\/OTT.S50945","volume":"6","author":"J Liang","year":"2013","unstructured":"Liang J, Mingyan E, Wu G, Zhao L, Li X, Xiu X, et al. Nimotuzumab combined with radiotherapy for esophageal cancer: preliminary study of a phase II clinical trial. Onco Targets Ther. 2013;6:1589\u201396.","journal-title":"Onco Targets Ther"},{"issue":"6","key":"631_CR22","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1007\/s00280-010-1422-x","volume":"67","author":"K Kato","year":"2011","unstructured":"Kato K, Tahara M, Hironaka S, Muro K, Takiuchi H, Hamamoto Y, et al. A phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapy. Cancer Chemother Pharmacol. 2011;67(6):1265\u201372.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"631_CR23","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/cas.12894","volume":"107","author":"M Lu","year":"2016","unstructured":"Lu M, Wang X, Shen L, Jia J, Gong J, Li J, et al. Nimotuzumab plus paclitaxel and cisplatin as the first line treatment for advanced esophageal squamous cell cancer: a single centre prospective phase II trial. Cancer Sci. 2016;107(4):486\u201390.","journal-title":"Cancer Sci"},{"issue":"15","key":"631_CR24","doi-asserted-by":"publisher","first-page":"4078","DOI":"10.1200\/jco.2014.32.15_suppl.4078","volume":"32","author":"G Castro","year":"2014","unstructured":"Castro G, Skare NG, Andrade CJ, Segalla J, Jobim De Azevedo S, Silva ID et al. Chemoradiation with or without nimotuzumab in locally advanced esophageal cancer (LAEC): a randomized phase II study (NICE trial). J Clin Oncol. 2014;32(15):4078. \n                        https:\/\/doi.org\/10.1200\/jco.2014.32.15_suppl.4078\n                        \n                    .","journal-title":"J Clin Oncol"},{"issue":"22","key":"631_CR25","doi-asserted-by":"crossref","first-page":"33391","DOI":"10.18632\/oncotarget.8516","volume":"7","author":"S Xu","year":"2016","unstructured":"Xu S, Ramos-Suzarte M, Bai X, Xu B. Treatment outcome of nimotuzumab plus chemotherapy in advanced cancer patients: a single institute experience. Oncotarget. 2016;7(22):33391\u2013407.","journal-title":"Oncotarget"},{"issue":"1","key":"631_CR26","first-page":"5","volume":"3","author":"R Perez","year":"2014","unstructured":"Perez R, Moreno E. EGFR-targeting therapy as an evolving concept: learning from nimotuzumab clinical development. Chin Clin Oncol. 2014;3(1):5.","journal-title":"Chin Clin Oncol"},{"key":"631_CR27","first-page":"117","volume":"9","author":"C Wang","year":"2016","unstructured":"Wang C, Fu X, Cai X, Wu X, Hu X, Fan M, et al. High-dose nimotuzumab improves the survival rate of esophageal cancer patients who underwent radiotherapy. Onco Targets Ther. 2016;9:117\u201322.","journal-title":"Oncotargets Ther"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-017-0631-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-017-0631-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-017-0631-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,11,30]],"date-time":"2017-11-30T03:57:47Z","timestamp":1512014267000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-017-0631-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,13]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["631"],"URL":"https:\/\/doi.org\/10.1007\/s12325-017-0631-7","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,13]]}}}